Medicines adherence and medicines optimisation inseparable, RPS tells NICE
Medicines adherence and medicines optimisation are inseparable, argues the Royal Pharmaceutical Society in response to a National Institute for Health and Care Excellence scoping exercise. NICE excludes the concept of medicines adherence from its draft scope on medicines optimisation.
“We strongly believe that it is not possible to separate medicines optimisation and medicines adherence. The ultimate goal of medicines optimisation is to ensure better adherence to medicines with the aim of getting the best outcomes for patients from their medicines. Medicines optimisation without medicines adherence is pointless,” the RPS says. It adds: “The two are inseparable, in our opinion as even if you prescribe the right medicines for the right patient at the right time, if the patient is not supported to take that medicine through a shared decision-making process then they are unlikely to achieve the best outcomes possible.”
The RPS also points out that medicines adherence, and therefore, medicines optimisation, could result in patients choosing not to take a particular medicine as part of an informed, shared decision-making process.
It notes that NICE’s earlier adherence advice will be signposted as an additional resource in the medicines optimisation guidance, but argues that medicines adherence should be integral to the medicines optimisation recommendations.
The RPS also criticises the definition of medicines optimisation in NICE’s scope, adding that it should be more “positive, and action and patient focused”.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11128499
Recommended from Pharmaceutical Press